Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Syphilis, caused by Treponema pallidum subspecies pallidum (T. pallidum), remains a significant global health problem despite being preventable and curable. The pathogen's ability to evade the immune system using virulence factor-based strategies and by invading immune-privileged sites enables persistent infection in the untreated host. This translational update describes the host innate and adaptive immune responses in syphilis and the sophisticated mechanisms employed by T. pallidum to avoid immune clearance. Recent advances in immune profiling have enhanced our understanding of the host immune response and identified potential biomarkers for disease staging and treatment monitoring. However, knowledge gaps remain regarding T. pallidum's immune evasion mechanisms, the dynamics of cellular and humoral immunity, and the characteristics of long-term protective immune responses against T. pallidum. Bridging these gaps by integrating microbiology, immunology, and multiomics approaches is crucial for advancing diagnostic tools, therapeutic strategies, and vaccine development to ultimately reduce the global burden of syphilis.

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jiaf388DOI Listing

Publication Analysis

Top Keywords

immune
9
host immune
8
immune response
8
immune evasion
8
immune responses
8
pallidum
5
syphilis
4
syphilis pathogenesis
4
host
4
pathogenesis host
4

Similar Publications

Immune intervention is dispensable for retinoic acid/arsenic therapy of murine acute promyelocytic leukemia.

Haematologica

September 2025

Université Paris-Cité, INSERM U1342, CNRS EMR8000, IRSL, Hôpital Saint-Louis, Paris, France; Collège de France, Chaire d'Oncologie Cellulaire et Moléculaire, PSL Research University, and INSERM U1050, CNRS UMR 7241, Paris, France; Service d'hématologie biologique, Hôpital Saint-Louis, AP/HP,

Not available.

View Article and Find Full Text PDF

The rapid increase in multidrug-resistant (MDR) bacteria and biofilm-associated infections has intensified the global need for innovative antimicrobial strategies. Phage therapy offers promising precision against MDR pathogens by utilizing the natural ability of phages to specifically infect and lyse bacteria. However, their clinical application is hampered by challenges such as narrow host range, immune clearance and limited efficacy within biofilms.

View Article and Find Full Text PDF

New strategies to enhance the efficacy of PD-1/PD-L1 inhibitors in treating microsatellite stable colorectal cancer.

Future Oncol

September 2025

Department of General Surgery, Institute of General Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou University, Yangzhou, China.

Immune checkpoint therapy has demonstrated significant potential in the treatment of various solid tumors. Among these, tumor-induced immunosuppression mediated by programmed cell death protein 1 (PD-1) represents a critical checkpoint. PD-1/programmed death-ligand 1 (PD-L1) inhibitors have been proven to exhibit substantial efficacy in solid tumors such as melanoma and bladder cancer.

View Article and Find Full Text PDF

Major ABO-Incompatible Platelet Transfusions Are Associated With Brain Ischemia After Intracerebral Hemorrhage.

Stroke

September 2025

Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York. (F.C.P., M.R., M.S., A.K., S.G., S.A., S.P., J.C., D.J.R.).

Background: Major ABO-incompatible platelet transfusions are associated with poor intracerebral hemorrhage (ICH) outcomes, yet drivers for this relationship remain unclear. Brain magnetic resonance imaging (MRI) ischemic lesions after ICH are neuroimaging biomarkers of secondary brain injury and are associated with poor outcomes. Given that ABO-incompatible platelet transfusions can induce immune complex formation, thrombo-inflammation, and endothelial barrier disruption, factors that could exacerbate cerebral ischemia, we explored whether major ABO-incompatible platelet transfusions are risk factors for ischemic lesions on brain MRI after ICH.

View Article and Find Full Text PDF